LakeShore Biopharma Co., Ltd

Ms. Zhiyuan  Ran

Head of Medical & Marketing Department

Dr. Zenaida Reynoso  Mojares M.D.

Chief Medical Officer

Mr. Wang  Xu

Chief Executive Officer & Director

Dr. Yuan  Liu Ph.D.

Head of Vaccine Research

Dr. Hui  Shao C.F.A., M.B.A., Ph.D.

President, Chief Business Officer & Vice Chairman

Ms. Rui  Yu M.B.A., M.S.

Chief Financial Officer & Director

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.

Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY Gross margin increased to 82.6% from 80.9% in the same period of FY2024 Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY Recorded net income of RMB 20.6 million, and adjusted net income[1] (Non-GAAP) of RMB 30.4 million, compared to net loss and adjusted net loss[1] (Non-GAAP) of RMB 174.5 million in the same period of FY2024 BEIJING , Dec. 19, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its financial results for the first six months ended September 30, 2024 ("FY2025H1").

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a leading global biopharmaceutical company focused on the innovation and production of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Shenyang Municipal Public Security Bureau in China (the “Bureau”) has initiated criminal investigations into actions taken by former chairman of the board of directors Yi Zhang (“Former Chairman”).

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB” or “the Company”), (NYSE: LXU) today announced the publication of its 2023 Sustainability Report, highlighting the Company's progress in advancing its sustainability efforts. LSB remains focused on its vision of being a leader in the clean energy transition through the production and delivery of low carbon products to multiple end markets. Additionally, the Company prioritizes its involvement in activities that support the long-term su.

LSB Industries Announces Publication of 2023 Sustainability Report

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB” or “the Company”), (NYSE: LXU) today announced that it has appointed John Chandler as an independent member of the Board of Directors (the “Board”) effective November 7, 2024. Mr. Chandler was also appointed to the audit committee of the Board. Mr. Chandler has more than 30 years of experience in the energy industry, predominantly in financial leadership and business development roles. Most recently, he served as Chief Financial Office.

LSB Industries, Inc. Appoints John Chandler as an Independent Member of the Board of Directors

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB” or the “Company”) today announced results for the third quarter ended September 30, 2024. Third Quarter 2024 Results and Recent Highlights Net sales of $109.2 million compared to $114.3 million in the third quarter of 2023 Net loss of $25.4 million compared to a net loss of $7.7 million in the third quarter of 2023; the third quarter 2024 net loss included approximately $16.3 million of turnaround costs and approximately $5.

LakeShore Biopharma Co., LtdLSB

LakeShore Biopharma Co., Ltd
LSB